» Articles » PMID: 23442192

PDT Dose Parameters Impact Tumoricidal Durability and Cell Death Pathways in a 3D Ovarian Cancer Model

Overview
Date 2013 Feb 28
PMID 23442192
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The successful implementation of photodynamic therapy (PDT)-based regimens depends on an improved understanding of the dosimetric and biological factors that govern therapeutic variability. Here, the kinetics of tumor destruction and regrowth are characterized by systematically varying benzoporphyrin derivative (BPD)-light combinations to achieve fixed PDT doses (M × J cm(-2)). Three endpoints were used to evaluate treatment response: (1) Viability evaluated every 24 h for 5 days post-PDT; (2) Photobleaching assessed immediately post-PDT; and (3) Caspase-3 activation determined 24 h post-PDT. The specific BPD-light parameters used to construct a given PDT dose significantly impact not only acute cytotoxic efficacy, but also treatment durability. For each dose, PDT with 0.25 μM BPD produces the most significant and sustained reduction in normalized viability compared to 1 and 10 μM BPD. Percent photobleaching correlates with normalized viability for a range of PDT doses achieved within BPD concentrations. To produce a cytotoxic response with 10 μM BPD that is comparable to 0.25 and 1 μM BPD a reduction in irradiance from 150 to 0.5 mW cm(-2) is required. Activated caspase-3 does not correlate with normalized viability. The parameter-dependent durability of outcomes within fixed PDT doses provides opportunities for treatment customization and improved therapeutic planning.

Citing Articles

Overcoming the effects of fluid shear stress in ovarian cancer cell lines: Doxorubicin alone or photodynamic priming to target platinum resistance.

Overchuk M, Rickard B, Tulino J, Tan X, Ligler F, Huang H Photochem Photobiol. 2024; 100(6):1676-1693.

PMID: 38849970 PMC: 11568959. DOI: 10.1111/php.13967.


Photosensitized co-generation of nitric oxide and singlet oxygen Enhanced toxicity against ovarian cancer cells.

Sanchez-Cruz P, Vazquez K, Lozada E, Valiyeva F, Sharma R, Vivas P J Nanopart Res. 2023; 24(4).

PMID: 37035485 PMC: 10081534. DOI: 10.1007/s11051-022-05463-x.


Photodynamic Priming Overcomes Per- and Polyfluoroalkyl Substance (PFAS)-Induced Platinum Resistance in Ovarian Cancer.

Rickard B, Tan X, Fenton S, Rizvi I Photochem Photobiol. 2022; 99(2):793-813.

PMID: 36148678 PMC: 10033467. DOI: 10.1111/php.13728.


Subcutaneous Xenograft Models for Studying PDT In Vivo.

Obaid G, Hasan T Methods Mol Biol. 2022; 2451:127-149.

PMID: 35505015 PMC: 10516195. DOI: 10.1007/978-1-0716-2099-1_10.


Analysis of Treatment Effects on Structurally Complex Microtumor Cultures Using a Comprehensive Image Analysis Procedure.

Bulin A, Broekgaarden M, Hasan T Methods Mol Biol. 2022; 2451:59-70.

PMID: 35505010 DOI: 10.1007/978-1-0716-2099-1_5.


References
1.
Sheng C, Hoopes P, Hasan T, Pogue B . Photobleaching-based dosimetry predicts deposited dose in ALA-PpIX PDT of rodent esophagus. Photochem Photobiol. 2007; 83(3):738-48. DOI: 10.1562/2006-09-07-RA-1033. View

2.
Whitacre C, Satoh T, Xue L, Gordon N, Oleinick N . Photodynamic therapy of human breast cancer xenografts lacking caspase-3. Cancer Lett. 2002; 179(1):43-9. DOI: 10.1016/s0304-3835(01)00853-9. View

3.
Guyon L, Ascencio M, Collinet P, Mordon S . Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer. Photodiagnosis Photodyn Ther. 2012; 9(1):16-31. DOI: 10.1016/j.pdpdt.2011.08.003. View

4.
Granville D, LEVY J, Hunt D . Photodynamic therapy induces caspase-3 activation in HL-60 cells. Cell Death Differ. 2003; 4(7):623-8. DOI: 10.1038/sj.cdd.4400286. View

5.
Gomer C, Ferrario A, Luna M, Rucker N, Wong S . Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med. 2006; 38(5):516-21. DOI: 10.1002/lsm.20339. View